EML4-ALK fusion gene is present in 2-7% of non-small cell lung cancers. Crizotinib was approved by FDA almost a year ago, and very recently European Medicines Agency recommended granting a conditional approval in patients with ALK+ non-small cell lung cancer. A recent University of Colorado Cancer Center case study, published in the Journal of Thoracic Oncology, describes the never before seen case of a patient who has been tested negative for EML4-ALK fusion based on the well defined criteria for FISH assay as approved by FDA, but nevertheless experienced remission after treatment with crizotinib. Read more here.
Study mentioned: Peled N, et al. Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non-Small-Cell Lung Cancer. J Thorac Oncol. 2012 Sep;7(9):e14-6. PMID: 22895149
No comments:
Post a Comment